Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction
about
Categorization of humans in biomedical research: genes, race and diseaseThe A's, G's, C's, and T's of health disparitiesThe inclusion of minority groups in clinical trials: problems of under representation and under reporting of data.Theory and methods in cultural neuroscienceThe 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs.The spectre of race in American medicine.Adrenergic alpha-1 pathway is associated with hypertension among Nigerians in a pathway-focused analysis.Role of race in the pharmacotherapy of heart failure.Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review.Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failureOptimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals.Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome.Predictors of blood pressure response in the SYMPLICITY HTN-3 trialRace and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure.Cardiovascular pharmacogenomics: current status, future prospects.Normal exercise blood pressure response in African-American women with parental history of hypertensionPharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.Pharmacological and cultural considerations in alcohol treatment clinical trials: issues in clinical research related to race and ethnicity.Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trialCultural constructions of health and illness. Recent cultural changes toward a holistic approach.Ethnicity and variation in prognosis for patients newly hospitalised for heart failure: a matched historical cohort study.Haplotype variation in the ACE gene in global populations, with special reference to India, and an alternative model of evolution of haplotypes.Heart failure management in African Americans: meeting the challenge.Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure.Prognosis for South Asian and white patients newly admitted to hospital with heart failure in the United Kingdom: historical cohort study.Heart failure--the importance of ethnicity.Electrocardiographic Left Ventricular Hypertrophy Among Gambian Diabetes Mellitus Patients.Valsartan in chronic heart failure.Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus WhitesSystems Pharmacology Links GPCRs with Retinal Degenerative Disorders.Future prospects of anticytokine therapy in chronic heart failure.Race, socioeconomic status, and health: complexities, ongoing challenges, and research opportunities.Out-patient management of chronic heart failure.Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.The renin-angiotensin system and right ventricular structure and function: The MESA-Right Ventricle Study.Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure.A review of the ethnic differences in breast cancer.Racial disparities in acute outcomes of life-threatening injury.
P2860
Q21999793-0BC8F421-F84B-465F-94C0-A10656944C88Q28752470-C098A45A-34E1-448B-9448-01A4110FFCCDQ30986560-53D15A7A-877F-4EE1-978D-5E03CAB38711Q33622217-930B6926-D9A8-4FBA-B284-8FE0EACD666CQ33916607-BA4EA1EA-BDEC-461B-AF79-A218368C2F38Q34039428-2F772984-618C-4896-99B4-4B2898D21820Q34277798-2043B4F3-132D-4543-B8CC-B74F1EA4C573Q34564305-950C936B-71F9-49AB-8CAC-5A7D2FF0F388Q34623044-82A81268-E31F-4BE7-B148-FD0C86644DDBQ34793905-D317F7AF-780A-462D-9E7A-D9A3246EF122Q34923747-C7109A9B-D352-4A87-B134-E4B603074052Q34980092-028239E7-09FE-4821-8571-BD51E173F2A0Q34982750-CD32E5A9-69F6-43EC-ACBF-748A24223F65Q34994094-18509FA0-3C22-4B0E-80FD-E4F9B1B91397Q35088348-5443CF75-F373-438B-AAA6-D41806D8EC45Q35090469-03629189-6A07-4B9A-A001-95FDD9A5F24EQ35194991-87593478-2D8E-4184-9B71-FDE4C0AB8EC0Q35207593-DEFF66CA-6E1D-4E38-9B50-001C924958DAQ35216008-6F2D751F-5D3E-4BEA-87B0-930454F9D6FAQ35551196-59FBBC64-CBC0-4EDB-8D30-B88E06767D48Q35551476-BB665E0D-7B04-4239-A694-A301A7A0C069Q35585101-F545ACFF-6B6E-4DC5-B263-3ADB908B86DCQ35613947-14C67969-E011-45C5-9868-F861EFA9EE62Q35741761-49BFD65B-62D5-4FC1-A1C0-B58187707EBFQ35820248-82CB47A0-E0A1-47E5-93DA-78359A823DBBQ35905991-8C3FEAB8-B301-4278-8959-61289C968C21Q35958227-672F0291-D2C0-42B3-A24D-F48EE55FE830Q35996797-4845F2E7-B912-4249-A529-2C5017F20295Q36027661-52113403-DD9F-4B6C-B130-27E32548B625Q36053760-58607ED7-4A62-49B0-A213-F3B3F6BA732FQ36087088-D1122574-3FA1-4928-A0C8-CCD4F633B8DCQ36087238-BEDDAC3E-72B6-4630-9E8C-1E536B424FB0Q36234930-8319FE1F-EB16-41FD-91FD-126108B72BE6Q36249926-0A3EEF02-12DA-4224-8A57-88BEED47DECCQ36326202-48D90720-3723-4ECA-9076-E324FE7222CBQ36366106-FC01EE4A-231F-4CE1-AF76-29B3BCC0462AQ36392987-D660FAD1-1E59-4FDB-9130-BE485D4EC9D8Q36559988-CF93848D-18AF-4A38-9035-F618D13DB3E1Q36596729-1BC76A8F-8FE3-43F5-BD83-7F9589D8D0FBQ36624835-C0A586CC-59DA-4C4E-A044-1CBB42F62841
P2860
Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Lesser response to angiotensin ...... h left ventricular dysfunction
@ast
Lesser response to angiotensin ...... h left ventricular dysfunction
@en
Lesser response to angiotensin ...... h left ventricular dysfunction
@nl
type
label
Lesser response to angiotensin ...... h left ventricular dysfunction
@ast
Lesser response to angiotensin ...... h left ventricular dysfunction
@en
Lesser response to angiotensin ...... h left ventricular dysfunction
@nl
prefLabel
Lesser response to angiotensin ...... h left ventricular dysfunction
@ast
Lesser response to angiotensin ...... h left ventricular dysfunction
@en
Lesser response to angiotensin ...... h left ventricular dysfunction
@nl
P2093
P1476
Lesser response to angiotensin ...... h left ventricular dysfunction
@en
P2093
P304
P356
10.1056/NEJM200105033441802
P407
P577
2001-05-03T00:00:00Z